Danazol therapy in myelodysplasia.
Platelet-associated IgG was markedly elevated in three patients with myelodysplasia and severe thrombocytopenia that had become refractory to platelet transfusions. The patients were treated with danazol because of its efficacy in treating immune thrombocytopenic purpura where platelet destruction is primarily mediated by IgG autoantibodies. After danazol therapy, the platelet counts of each patient rose and clinical bleeding stopped, and a decline in hemolysis was seen in two patients. Danazol probably impeded the peripheral clearance of cells by macrophages; however, a beneficial effect of danazol on hematopoiesis cannot be excluded.
D000368:Aged; D001772:Blood Cell Count; D001792:Blood Platelets / Q000276:immunology; D001803:Blood Transfusion; D001855:Bone Marrow Diseases / Q000097:blood / Q000188:drug therapy*; D003131:Combined Modality Therapy; D003613:Danazol / Q000627:therapeutic use*; D017707:Erythrocyte Transfusion; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D008297:Male; D017713:Platelet Transfusion; D011245:Pregnadienes / Q000627:therapeutic use*; D013156:Splenectomy; D013921:Thrombocytopenia / Q000188:drug therapy* / Q000209:etiology
D007074:Immunoglobulin G; D011245:Pregnadienes; D003613:Danazol